drugset
drugset / Trial / NCT00367783

Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

NCT00367783 ↗

Phase 2 Terminated 100 enrolled Pfizer
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether CP-741,952 is effective in the treatment of obesity and to determine 12 week safety and toleration.

Timeline

Start
2006-06
Primary completion
—
Completion
2007-04

Outcome

Outcome not reported

Stopped: “See Detailed Description for termination reason.”

Drugs

EvaluationDrugModalityDoseRoute
Subject CP-741,952 Unknown — —

Indications

obesity disorder